title: The expression level of lysophosphatidylcholine acyltransferase 1 (LPCAT1) correlates to the progression of prostate cancer.
abstract: BACKGROUND
  Lysophosphatidylcholine acyltransferase 1 (LPCAT1), the enzyme catalyzing the reaction in remodeling of phosphatidylcholine (PC) has been reported to express in prostate. However, its diagnostic and prognostic values remain unclear.
  
  
  METHODS
  Immunohistochemistry (IHC) for LPCAT1 was performed on the tissue microarray (TMA) slides containing 251 samples from 148 patients with various prostatic disorders. The association of expression level of LPCAT1 with the progression of prostate cancer was analyzed.
  
  
  RESULTS
  LPCAT1 IHC mean score was the highest in metastatic prostate cancer (8.00±1.28), which was significantly higher than that in primary prostate cancer (4.63±3.00, p=9.73E-07), in high grade prostatic intraepithelial neoplasia (HGPIN, 2.72±2.47, p=1.02E-12), and in benign prostate (2.68, p=6.17E-12). The mean score in primary prostate cancer was significantly higher than that in HGPIN (p=4.09E-04) and in benign prostate (p=2.74E-04). There was no significant difference in the mean score between HGPIN and benign prostate (p=0.951). LPCAT1 IHC score also correlated to the tumor grade and stage of prostate cancer. Patients who underwent prostatectomy for prostate cancer and developed biochemical recurrence or clinical metastasis had higher LPCAT1 IHC score than those who underwent prostatectomy for prostate cancer and did not develop biochemical recurrence and clinical metastasis. The association of LPCAT1 with the progression of prostate cancer was independent of patient race and age, PSA level and positivity of surgical resection margins.
  
  
  CONCLUSIONS
  LPCAT1 correlates with the progression of prostate cancer and could be a new biomarker in diagnosis, prognosis and studying the pathogenesis of prostate cancer.
authors.affiliation: Department of Pathology University of Mississippi Medical Center, Jackson, MS 39216, USA. xzhou@umc.edu
authors.forename: Xinchun
authors.initials: X
authors.lastname: Zhou
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Lawrence
authors.forename: Zhi
authors.initials: Z
authors.lastname: He
authors.forename: Charles R
authors.initials: CR
authors.lastname: Pound
authors.forename: Jinghe
authors.initials: J
authors.lastname: Mao
authors.forename: Steven A
authors.initials: SA
authors.lastname: Bigler
mesh_terms: D008243:1-Acylglycerophosphocholine O-Acyltransferase / Q000378:metabolism*; D000368:Aged; D015415:Biomarkers; D018450:Disease Progression; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D016612:Paraffin Embedding; D011379:Prognosis; D011467:Prostate / Q000201:enzymology* / Q000473:pathology / Q000601:surgery; D017430:Prostate-Specific Antigen / Q000378:metabolism; D011468:Prostatectomy; D019048:Prostatic Intraepithelial Neoplasia / Q000378:metabolism / Q000473:pathology* / Q000556:secondary / Q000601:surgery; D011471:Prostatic Neoplasms / Q000378:metabolism / Q000473:pathology* / Q000601:surgery
chemical_list: D015415:Biomarkers; D008243:1-Acylglycerophosphocholine O-Acyltransferase; D017430:Prostate-Specific Antigen
references.citation: J Biol Chem. 1956 Sep;222(1):193-214
references.pmid: 13366993
references.citation: Front Biosci. 2006 May 01;11:1388-413
references.pmid: 16368524
references.citation: Proc Natl Acad Sci U S A. 2010 Aug 31;107(35):15523-8
references.pmid: 20713727
references.citation: Urology. 1998 Jun;51(6):985-90
references.pmid: 9609637
references.citation: J Biol Chem. 2006 Jul 21;281(29):20140-7
references.pmid: 16704971
references.citation: Am J Physiol Endocrinol Metab. 2009 Dec;297(6):E1276-82
references.pmid: 19773578
references.citation: Prostate. 2008 Jul 1;68(10):1035-47
references.pmid: 18459103
references.citation: Prog Lipid Res. 2000 May;39(3):257-88
references.pmid: 10799718
references.citation: J Urol. 1990 Nov;144(5):1180-4
references.pmid: 2231891
references.citation: IUBMB Life. 2006 May-Jun;58(5-6):328-33
references.pmid: 16754327
references.citation: J BUON. 2009 Jul-Sep;14(3):501-6
references.pmid: 19810145
references.citation: Curr Opin Urol. 2010 May;20(3):185-8
references.pmid: 20224413
references.citation: J Urol. 1996 Jul;156(1):243-8
references.pmid: 8648815
references.citation: Biochim Biophys Acta. 2000 Jan 3;1483(1):1-14
references.pmid: 10601692
references.citation: Urology. 1999 Jan;53(1):126-30
references.pmid: 9886601
references.citation: Biochim Biophys Acta. 2005 Mar 21;1733(1):53-66
references.pmid: 15749057
references.citation: J Mol Med (Berl). 2009 Jan;87(1):85-97
references.pmid: 18974965
references.citation: Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11724-9
references.pmid: 16864775
references.citation: J Lipid Res. 2009 Sep;50(9):1824-31
references.pmid: 19383981
references.citation: Urology. 2005 Dec;66(6):1245-50
references.pmid: 16360451
references.citation: J Biol Chem. 2011 Aug 12;286(32):28019-25
references.pmid: 21685381
references.citation: Urol Oncol. 2010 Mar-Apr;28(2):197-204
references.pmid: 20219559
references.citation: J Endocrinol. 2007 Jun;193(3):445-57
references.pmid: 17535882
references.citation: J Clin Invest. 2010 May;120(5):1736-48
references.pmid: 20407208
references.citation: J Biol Chem. 1958 Apr;231(2):883-8
references.pmid: 13539023
references.citation: J Urol. 2001 Feb;165(2):463-8
references.pmid: 11176397